Brokerage Firm Rating Update on Mallinckrodt plc (MNK)

Mallinckrodt plc (MNK) : Zacks Investment Research ranks Mallinckrodt plc (MNK) as 2, which is a Buy recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 13 research analysts is 1.04, which indicates as a Strong Buy.

Mallinckrodt plc (MNK) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $115 and the lowest price target forecast is $82. The average forecast of all the analysts is $94.83 and the expected standard deviation is $10.55.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Deutsche Bank maintains the rating on Mallinckrodt plc (NYSE:MNK). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency lowers the price target from $87 per share to $84 per share. The rating by the firm was issued on August 31, 2016.

Mallinckrodt plc (NYSE:MNK): stock was range-bound between the intraday low of $73.64 and the intraday high of $76.62 after having opened at $74.94 on Wednesdays session. The stock finally closed in the red at $74.94, a loss of -0.49%. The stock remained in the red for the whole trading day. The total traded volume was 1,290,888 shares. The stock failed to cross $76.62 in Wednesdays trading. The stocks closing price on Thursday was $74.92.

Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.